Navigation Links
Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Date:6/2/2011

ANN ARBOR, Mich., June 2, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today positive findings based on further analyses from the clinical study evaluating reaZin along with near-term plans for its Alzheimer's disease program. After reviewing the statistical analysis with the Company's scientific advisors, Adeona intends to conduct another Alzheimer's disease clinical study to evaluate its proprietary zinc-based tablet in patients age 70 and over. In parallel, Adeona intends to make reaZin commercially available as a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease.

After presenting the top-line results in April from the clinical study evaluating reaZin that demonstrated, on average, that the cognitive function (as measured by three standardized cognitive tests) of the patients managed with reaZin remained relatively stable over six months, while the placebo group showed deterioration, Adeona conducted further analyses to determine if certain subgroups in the patient sample benefitted from reaZin more than others.

After analyzing a number of independent variables associated with the patients enrolled in the clinical study on a post-hoc basis, the strongest relationship was found to be between age and cognitive outcomes. Patients in the study ranged from 52 to 86 years of age. Patients in the placebo group, on average, showed age-related cognitive decline – the older the patient, the greater the rate of cognitive decline. In contrast, patients in the reaZin treatment group, on average, showed cognitive stabilization, no matter what their age. Therefore, the older the reaZin treatment patient, the greater the amount of cognitive benefit comp
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
2. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... 2015 , ... Proove Biosciences , a commercial and ... Advisory Board meeting in Palm Springs, California. At the bi-annual meeting, the Medical ... new clinical practice and research ideas. The Board also discussed the development of ...
(Date:7/6/2015)... Tenn. , July 6, 2015 /PRNewswire/ ... entered into a definitive agreement to acquire ... and intervention platforms that combine data aggregation ... reporting capabilities to achieve actionable insights and ... will combine Altegra Health,s risk adjustment and ...
(Date:7/6/2015)... , June 29, 2015 ... has announced the addition of the "Biotechnology ... Biotechnology for the Non-Biotechnologist, ideal for ... theory, principles, techniques and potential of biotechnology. ... understand the basic theory, principles, techniques, and potential ...
(Date:7/6/2015)... PRINCETON, N.J. , July 6, 2015 Navitas, a leading ... Latin America hub in Bogota, Colombia ... advantage of the many benefits provided by Colombia , ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... location, allows US based clients to communicate with Navitas regulatory ...
Breaking Biology Technology:Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3
... Investigator Sites Now Available on goBalto.com , ... ... goBalto, an online drug development partnering site for the pharmaceutical ... is making its proprietary list of India-based Investigator Sites and ...
... - Completed Series B Total ... Opsona Therapeutics, a biotechnology company focused on novel therapeutic,and ... Roche Venture Fund and Enterprise Ireland have committed an,additional ... February,this year, bringing the total round to EUR21.3 million. ...
... May 18 Cell Therapeutics, Inc. (the "Company" or "CTI") ... its "Modified Dutch Auction" tender offer (the "Exchange Offer") to ... of its common stock, no par value (the "Common Stock"), ... principal amount of the following outstanding series of its convertible ...
Cached Biology Technology:goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites 2goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites 3Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 2Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 2Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 4Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 5
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... June 17, 2015  Synaptics Inc. (NASDAQ: ... today announced that Xiaomi, one of the world,s ... ClearPad ® family of capacitive touchscreen ... circuits (DDICs) for its latest smartphones, the Xiaomi ... for full in-cell display solutions and DDICs in ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... Calif. -- The National Institutes for Health (NIH) have ... researchers to engineer an artificial pancreas system that will ... in behavior and physiology. This collaboration between physicians and ... 1 diabetes management human behavior, physiology, and medical ...
... Southern Research Station (SRS) today announced the publication of a ... native bark beetle that impacts both the economic and ecological ... Southern pine beetle is the most destructive forest pest ... in damage and lost timber income annually. The most recent ...
... of genetics, lifestyle and environment on breast cancer in ... of Louisville School of Public Health & Information Sciences ... Denkhoff. Through a SPHIS Department of Epidemiology ... grant from Susan G. Komen for the Cure, the ...
Cached Biology News:NIH awards group $4.5 million for smart artificial pancreas technology 2NIH awards group $4.5 million for smart artificial pancreas technology 3'Southern Pine Beetle II' 2UofL students seek answers to breast cancer disparities in minority populations 2UofL students seek answers to breast cancer disparities in minority populations 3
...
...
... sensitive and specific detection of microRNAs (miRNAs) ... have high binding affinity and discrimination, enabling ... Due to the high binding affinity of ... the amount of sample is needed compared ...
... Mixes are optimised for SYBR Green I assays ... Quantitative PCR, with the exception of template and ... optimal levels of active SYBR Green I dye ... reaction buffer that enables detection of low copy ...
Biology Products: